- Home
- PULM vs BMRA Comparison
PULM vs BMRA Comparison
Compare PULM & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- BMRA
- Stock Information
- Founded
- PULM 2003
- BMRA 1971
- Country
- PULM United States
- BMRA United States
- Employees
- PULM N/A
- BMRA N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PULM Health Care
- BMRA Health Care
- Exchange
- PULM Nasdaq
- BMRA Nasdaq
- Market Cap
- PULM 18.3M
- BMRA 8.2M
- IPO Year
- PULM N/A
- BMRA N/A
- Fundamental
- Price
- PULM $5.13
- BMRA $2.98
- Analyst Decision
- PULM
- BMRA
- Analyst Count
- PULM 0
- BMRA 0
- Target Price
- PULM N/A
- BMRA N/A
- AVG Volume (30 Days)
- PULM 9.7K
- BMRA 432.3K
- Earning Date
- PULM 11-07-2025
- BMRA 10-14-2025
- Dividend Yield
- PULM N/A
- BMRA N/A
- EPS Growth
- PULM N/A
- BMRA N/A
- EPS
- PULM N/A
- BMRA N/A
- Revenue
- PULM $369,000.00
- BMRA $5,311,000.00
- Revenue This Year
- PULM N/A
- BMRA N/A
- Revenue Next Year
- PULM $134.88
- BMRA N/A
- P/E Ratio
- PULM N/A
- BMRA N/A
- Revenue Growth
- PULM N/A
- BMRA N/A
- 52 Week Low
- PULM $1.86
- BMRA $2.08
- 52 Week High
- PULM $10.40
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- PULM 52.75
- BMRA 50.90
- Support Level
- PULM $4.91
- BMRA N/A
- Resistance Level
- PULM $5.19
- BMRA $3.05
- Average True Range (ATR)
- PULM 0.13
- BMRA 0.20
- MACD
- PULM 0.08
- BMRA -0.10
- Stochastic Oscillator
- PULM 88.89
- BMRA 91.98
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.